Scholarlink

<p>A 67-year-old woman with a 25-year history of type 1 diabetes mellitus and comorbid Crohn’s disease developed rapidly progressive proteinuria, hypoalbuminemia, edema, and kidney dysfunction. Minimal change disease (MCD) was diagnosed on kidney biopsy. Mesalazine was discontinued, and prednisolone (PSL) at 50&#xa0;mg/day (0.9&#xa0;mg/kg) induced remission of MCD. During treatment, glycemic management markedly worsened, and multiple daily insulin injections failed to achieve adequate control. After edema improved and PSL was tapered to 35&#xa0;mg/day, continuous subcutaneous insulin infusion was resumed, and advanced hybrid closed-loop (AHCL) therapy was initiated using the MiniMed™ 780G system. Consequently, time in range markedly increased, accompanied by a significant decrease in time above range without a clinically significant increase in time below range. During PSL tapering, hypoglycemia was successfully prevented through automated basal rate adjustment by the AHCL system, optimization of the carbohydrate-to-insulin ratio, extension of active insulin time, setting of temporary glucose targets, and supplemental carbohydrate intake. This case suggests that MCD should be considered in the differential diagnosis of patients with Crohn’s disease or diabetes presenting with rapidly progressive proteinuria and kidney impairment. To prevent hypoglycemia and mitigate the limitations of automated delivery, device settings should be dynamically adjusted during steroid tapering to account for changes in insulin sensitivity. With this clinical management strategy, AHCL therapy may be an effective treatment option for steroid-induced hyperglycemia.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Minimal change disease in a patient with type 1 diabetes and Crohn’s disease managed with advanced hybrid closed-loop insulin therapy during corticosteroid treatment

  • 期刊论文

  • 发表日期：

    2026年5月15日

查看全文
  • Atsushi Sato,
  • Nozomi Harai,
  • Ryutaro Fumoto,
  • Yuya Suzuki,
  • Takayasu Uchida,
  • Kimio Matsumura,
  • Yusuke Yokoyama,
  • Akinari Sekine,
  • Akira Matsui,
  • Kei Kono,
  • Yutaka Takazawa,
  • Kenichi Ohashi,
  • Kaoru Nagasawa,
  • Yasumichi Mori

摘要

A 67-year-old woman with a 25-year history of type 1 diabetes mellitus and comorbid Crohn’s disease developed rapidly progressive proteinuria, hypoalbuminemia, edema, and kidney dysfunction. Minimal change disease (MCD) was diagnosed on kidney biopsy. Mesalazine was discontinued, and prednisolone (PSL) at 50 mg/day (0.9 mg/kg) induced remission of MCD. During treatment, glycemic management markedly worsened, and multiple daily insulin injections failed to achieve adequate control. After edema improved and PSL was tapered to 35 mg/day, continuous subcutaneous insulin infusion was resumed, and advanced hybrid closed-loop (AHCL) therapy was initiated using the MiniMed™ 780G system. Consequently, time in range markedly increased, accompanied by a significant decrease in time above range without a clinically significant increase in time below range. During PSL tapering, hypoglycemia was successfully prevented through automated basal rate adjustment by the AHCL system, optimization of the carbohydrate-to-insulin ratio, extension of active insulin time, setting of temporary glucose targets, and supplemental carbohydrate intake. This case suggests that MCD should be considered in the differential diagnosis of patients with Crohn’s disease or diabetes presenting with rapidly progressive proteinuria and kidney impairment. To prevent hypoglycemia and mitigate the limitations of automated delivery, device settings should be dynamically adjusted during steroid tapering to account for changes in insulin sensitivity. With this clinical management strategy, AHCL therapy may be an effective treatment option for steroid-induced hyperglycemia.